Project Grant R21HL184915
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $234K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Florida $782,085 on June 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify actionable multilevel intervention strategies to improve cardiovascular health among people with HIV. The project, titled "Identifying Actionable Multilevel Intervention Strategies to Improve Cardiovascular Health Among People With HIV," runs through February 28, 2031, with performance at Gainesville,...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $3,093,164 on June 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate an expanded HIV Synthesis microsimulation model incorporating hypertension and cardiovascular disease outcomes, evaluate health effects and cost-effectiveness of implementation strategies for HIV-hypertension care integration across West, East, and Southern Africa...
- The National Heart, Lung, and Blood Institute awarded $1.555 million to the University of Maryland, Baltimore on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to model and treat chronic HIV-induced lung infections. The research investigates immune mechanisms underlying increased susceptibility to respiratory infections in people living with HIV. The project focuses on how chronic HIV infection impairs dendritic cell differentiation and function, hypothesizing...
- The National Institute of Environmental Health Sciences, part of the National Institutes of Health, awarded the University of Texas Health Science Center at Houston $200,268 on September 1, 2026, under the Medical Library Assistance program (CFDA 93.879) for Project Grant R21LM015664. The recipient will develop DEEPHIV-AOU, a multi-modal deep learning framework designed to improve HIV prevention through personalized risk assessment and intervention planning. The framework integrates four...
- The National Heart, Lung, and Blood Institute awarded the University of Texas at Austin $238,858 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop personalized prediction models for HER2-induced cardiovascular adverse events in older women with breast cancer using artificial intelligence and machine learning. The award funds a cohort study using 2011–2022 Surveillance, Epidemiology, and End Results (SEER)–Medicare data linked with American...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $158,892 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine the impact of DNMT3A protein reduction on normal and clonal hematopoiesis. The research investigates mechanisms by which somatic DNMT3A mutations drive clonal hematopoiesis—the clonal expansion of mutated hematopoietic stem and progenitor cells—which accelerates with age and increases the risk of hematologic...
- The National Heart, Lung, and Blood Institute awarded the University of Connecticut Health Center $155,452 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for a five-year project grant (K01HL176409) to evaluate integrated HIV and non-communicable disease service delivery through mathematical modeling. The recipient will use mathematical modeling and data from the Center for Infectious Disease Research in Zambia's NIH-funded TASKPEN trial to assess the...
- The National Heart Lung and Blood Institute awarded New York University $510,538 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a hybrid effectiveness-implementation study integrating the HEARTS package—a World Health Organization–recommended strategy comprising healthy lifestyle counseling, evidence-based treatment protocols, access to medicines, risk-based care, task-sharing, and systems monitoring—into primary healthcare centers in Nigeria...
- The National Heart, Lung, and Blood Institute awarded Georgia TECH Research Corp $593,993 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop data-driven restless multi-armed bandit (RMAB) computational models that optimize allocation of public health interventions for diabetes, cardiovascular disease, and maternal health. The project delivers contextual, network-based, and multi-agent RMAB algorithms that integrate observational electronic health...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $3,229,552 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop DART-HIV, an artificial intelligence-driven framework for modeling physiological vulnerability and predicting adverse health outcomes in people living with HIV over a 10-year horizon. DART-HIV comprises two core components: a time-dependent risk trajectory forecasting four major adverse outcomes—all-cause...